📌 Key Takeaways
- Topic: Silica Whiteness: How It Is Measured and Why It Matters for Coatings and Rubber
- Keywords: HDK N20
- Published: 2026-11-20 09:29:20
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica Specification Sheet: Key Parameters to Check Before Buying
- Silica Nanoparticles: Synthesis, Properties, Safety and Applications
- Chong, Y., Liu, Q. & Ge, C. Advances in oxidase-mimicking nanozymes: Classification, activity regulation and biomedical applications. Nano Today 37, 101076 (2021). Article CAS Google Scholar
- Silicon Dioxide Chemical Properties: Reactivity, Stability and Key Reactions
- Pelaz, B. et al. Surface functionalization of nanoparticles with polyethylene glycol: effects on protein adsorption and cellular uptake. ACS Nano 9, 6996-7008 (2015). Post CAS PubMed Google Scholar
- What Is Surface Treated Silica? Treatment Methods, Benefits and Applications
- Spherical vs Angular Silica: Which Filler Performs Better and When?
- Gene therapy refers to the introduction of exogenous genes into the target cells to treat diseases by replacing defective genes or adding new genes. 452, 453 In many cases, the core of gene therapy lies in the selection of a fitting gene vector to efficiently deliver the gene to the target cells. 454, 455 Viral vectors are frequently used in clinical settings, and even though they have high efficiency in gene transfection, their safety issue, i.e., causing adverse immune response in the body, cannot be ignored. 454 MSNs, as brilliant multifunctional non-viral vectors, have advantages in biocompatibility, tissue toxicity, and targeting. 456, 457 As early as 2004, MCM-41-type MSNs were used as gene transfection reagents for delivery of plasmid DNA. 52 Since then, many different gene therapy tactics have been developed based on MSNs, and their therapeutic effects have been validated in the fields of tumor therapy, 458, 459, 460 diabetes treatment, 378 and wound healing. 461, 462 As an example, suicide gene therapy as a gene-mediated enzyme prodrug treatment, is able to kill tumor cells specifically after in situ conversion of the drug into toxic drugs. 463 To control the synergistic intracellular release of suicide genes and prodrugs and enhance therapeutic efficacy, Wang et al. investigated the efficacy of spherical and rod-shaped magnetic MSNs in targeted drug delivery, and gene transfection, MRI imaging, and hepatocellular carcinoma treatment. It was demonstrated that the Janus-type rod-like magnetic MSNs loaded with ganciclovir (GCV) and functionalized by PEG-g-PLL revealed better drug-loading ability and faster drug release behavior, indicating that they are a useful tool to build the herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) gene therapy system. 464
Alumina Powder vs Silica Powder: Properties, Uses and How to Choose
What is silica (SiO₂)?
silica molar mass Springer, C. J. & Niculescu-Duvaz, I. Prodrug-activating systems in suicide gene therapy. J. Clin. Investig. 105, 1161-1167 (2000). Article CAS PubMed Central PubMed Google Scholar
What is the difference between fumed silica and precipitated silica?
Nouryon Levasil Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
What drives silica raw material prices?
silica nanopowder
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.